Skip to Content

Intuitive Surgical Inc ISRG

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Intuitive's Strong Third-Quarter Revenue Growth Speaks of Recovery Despite Delta Variant

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We are maintaining our fair value estimate of $175 for wide-moat Intuitive Surgical following third-quarter results and preliminary data from the Ion endoluminal system’s multi-center clinical trial, PRECIsE. We currently view shares as overvalued.

Read Full Analysis

Company Profile

Business Description

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 6,000 da Vinci systems in hospitals worldwide, with nearly 4,000 installations in the United States and a growing number in emerging markets.

Contact
1020 Kifer Road
Sunnyvale, CA, 94086-5304
T +1 408 523-2100
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Aggressive Growth
Employees 8,081

Related